Skip to content
Search

Latest Stories

Flower named Afghanistan team consultant for T20 World Cup

Flower named Afghanistan team consultant for T20 World Cup

FORMER Zimbabwe captain and England coach Andy Flower has been named the Afghanistan team's consultant for the Twenty20 World Cup, the Afghanistan Cricket Board (ACB) said.

Flower played 63 Tests and 213 one-day international matches for Zimbabwe from 1992 to 2003, then coached England from 2009 to 2014, helping them win the T20 World Cup in 2010.


He has also coached in T20 leagues across the world, including the Indian Premier League and the Pakistan Super League.

"Andy has worked with a number of our players in various franchise completions and his vast experience will be very beneficial and useful to help the team in the World Cup," said Azizullah Fazli, the ACB's new chairman.

The T20 World Cup will be held in the United Arab Emirates and Oman from Oct. 17.

Afghanistan are in Group 2 alongside India, Pakistan, New Zealand and two qualifiers. They will be led by Mohammad Nabi at the World Cup after star player Rashid Khan stepped down from captaincy.

The Taliban, who took control of Afghanistan in August, have said they would not interfere with men's cricket, but the fate of the women's programme remains unclear.

The governing International Cricket Council (ICC) will discuss Afghanistan and women's cricket at its next board meeting during the World Cup.

Last month, Cricket Australia threatened to scrap a Test match against the men's team if the Taliban did not allow women to play the sport.

(Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less